

AGENUS INC
Form 8-K
June 14, 2011

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **June 14, 2011**

AGENUS INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction
of incorporation)

000-29089

(Commission File Number)

06-1562417

(IRS Employer Identification No.)

**3 Forbes Road
Lexington, MA**

(Address of principal executive offices)

02421

(Zip Code)

Registrant's telephone number, including area code: **781-674-4400**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Edgar Filing: AGENUS INC - Form 8-K

On June 14, 2011, Agenus Inc. announced a license agreement with Integrated BioTherapeutics Inc. (IBT) for the use of the QS-21 Stimulon® adjuvant in the development of a vaccine against Ebola and Marburg viruses. Under this agreement, Agenus is entitled to receive a license fee, program-based milestone payments and worldwide royalties on net sales of the vaccine product. IBT, a biotechnology company focused on development of medical countermeasures for biodefense and emerging infectious diseases, was awarded a multi-year contract in September 2008 for development of a vaccine to protect against Ebola and Marburg viruses from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated June 14, 2011

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AGENUS INC.

(Registrant)

/s/ **SHALINI SHARP**

June 14, 2011

(Date)

Shalini Sharp
Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated June 14, 2011